Rebecca A. Betensky, Ph.D., is professor of biostatistics at the Harvard School of Public Health and a biostatistician at Massachusetts General Hospital (MGH). She directs the statistical core of the Alzheimer’s Disease Research Center at MGH and she is co-leader of the Biostatistics Program at the Dana-Farber/Harvard Cancer Center. She graduated from Stanford University with a Ph.D. in 1992. Her current methodological research interests are in the areas of latent class modeling for genomic data and survival analysis under complex sampling and with auxiliary information. Dr. Betensky’s research involves the use of penalization, either in a frequentist or Bayesian setting, to enable model fitting with the high dimensional data. This research is motivated by problems that Dr. Betensky encounters in her collaborations in neuro-oncology and neurologic diseases.

Peter Como, Ph.D., joined the U.S. Food and Drug Administration (FDA) in 2009 as a lead reviewer and neuropsychologist in the Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices, Neurodiagnostic and Neurotherapeutic Devices Branch. He obtained his doctorate in clinical psychology/neuropsychology from the University of Delaware. Prior to joining the FDA, Dr. Como was an associate professor of neurology, psychiatry, and brain and cognitive science at the University of Rochester Medical Center for 25 years. He served in a clinical capacity as a neuropsychologist in the Movement and Inherited Neurological Disorders Unit in the Department of Neurology. Dr. Como was also a principal investigator in several clinical research studies (observational and clinical drug trials) in Huntington’s disease, Parkinson’s disease, and Tourette syndrome. Dr. Como has been invited to speak at major national and international meetings with respect to his expertise in neuropsychology, clinical trials, and neurological movement disorders. Dr. Como was part of the clinical investigative team who presented to an FDA advisory panel, which ultimately led to the approval of tetrabenazine for the treatment of chorea, associated with Huntington’s disease, in 2008.

Ray Dorsey, M.D., is an associate professor of neurology at The Johns Hopkins University where he directs the movement disorders division and neurology telemedicine. His research focuses on developing new treatments and improving the way health care is delivered, including the use of telemedicine, for neurological disorders. He previously was an assistant professor of neurology at the University of Rochester and an associate for the consulting firm, McKinsey & Company. He attended medical and business school at the University of Pennsylvania.

Charles E. Drebing, Ph.D., is the acting mental health service line manager at the Bedford Veterans Administration (VA) Medical Center, and the as

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement